Goldline Pharmaceutical Cash Flow Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Net Income	28.34	18.06	2.57	-	-
Depreciation & Amortization	2.5	1.64	1.75	-	-
Loss (Gain) From Sale of Assets	0.91	0.42	2.04	-	-
Other Operating Activities	18.35	21.38	17.28	-	-
Change in Accounts Receivable	-10.71	-9.95	-5.16	-	-
Change in Inventory	7.13	-21.2	0.91	-	-
Change in Accounts Payable	4.13	7.77	1.07	-	-
Change in Other Net Operating Assets	-27.44	11.11	3.47	-	-
Operating Cash Flow	23.21	29.22	23.91	-	-
Operating Cash Flow Growth	-20.57%	22.21%	-	-	-
Capital Expenditures	-2.07	-11.09	-11.08	-	-
Sale of Property, Plant & Equipment	3.78	-	0.98	-	-
Investment in Securities	-0.09	-	-0.25	-	-
Investing Cash Flow	1.62	-11.09	-10.35	-	-
Short-Term Debt Issued	7.64	0.6	25.96	-	-
Long-Term Debt Issued	-	2.41	-	-	-
Total Debt Issued	7.64	3.01	25.96	-	-
Long-Term Debt Repaid	-8.6	-	-22.04	-	-
Net Debt Issued (Repaid)	-0.96	3.01	3.92	-	-
Issuance of Common Stock	-	4.5	-	-	-
Preferred Dividends Paid	-2.15	-2.17	-2.17	-	-
Dividends Paid	-2.15	-2.17	-2.17	-	-
Other Financing Activities	-17.23	-16.12	-16.18	-	-
Financing Cash Flow	-20.34	-10.78	-14.43	-	-
Miscellaneous Cash Flow Adjustments	-0	-0	-	-	-
Net Cash Flow	4.5	7.36	-0.87	-	-
Free Cash Flow	21.14	18.14	12.83	-	-
Free Cash Flow Growth	16.58%	41.36%	-	-	-
Free Cash Flow Margin	7.54%	7.70%	6.46%	-	-
Free Cash Flow Per Share	3.06	3.02	2.14	-	-
Cash Interest Paid	16.24	14.77	15.2	-	-
Cash Income Tax Paid	9.13	1.95	0.35	-	-
Levered Free Cash Flow	0.09	-0.87	-7.63	-	-
Unlevered Free Cash Flow	11.64	8.37	1.97	-	-
Change in Working Capital	-26.89	-12.28	0.28	-	-